secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001558370-23-010962
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Coherus BioSciences stockholders elect directors, ratify auditor, approve say-on-pay at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected Class III directors Dennis M. Lanfear (57.4M for) and Mats L. Wahlström (42.6M for) to hold office until 2026.
- Ratified Ernst & Young as independent auditor for FY 2023 with 65.4M votes for, 0.4M against.
- Approved non-binding advisory say-on-pay resolution for named executive officers with 55.4M for, 3.2M against.
- Approximately 65.9M shares voted out of 80.5M shares outstanding as of April 10, 2023 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023010962/0001558370-23-010962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023010962/chrs-20230607x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-010962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer